JAPAN

Macquarie Marquee Ideas

New Marquee List Up/Down Shifting to OECD LI Analyst Name Company Name Rec % William Daiwa Industry OP 37.17 Event Montgomery William Hulic OP 72.08 . We adjust the Marquee Ideas list to reflect the recent call by Peter Montgomery Mike Allen Towa Pharmaceutical OP 36.59 Eadon-Clarke, our Head of Global Strategy, that OECD LI is inflecting and Polina Diyachkina OP 32.89 hence global cyclical stocks should outperform. Sumitomo Metal Damian Thong OP 26.98 . New additions (6): Nippon Steel (Outperform), (Outperform), Towa Corporation Damian Thong Corporation OP 56.73 Pharma (Outperform), MELCO (Outperform), Fanuc (Underperform) & Daiwa Kenjin Hotta Fanuc UP (16.43) House (Outperform). Maintain (3): Mitsubishi Corp (Outperform), Hulic Takuo Katayama Suzuki Motor OP 36.63 Polina Diyachkina Mitsubishi Corp OP 36.54 (Outperform), Panasonic (Outperform). Removals (5): Source: Macquarie Research, June 2016 (Outperform), Takara Leben (Outperform), Cookpad (Outperform), Kakaku.com (Underperform) & Matsumotokiyoshi (Outperform).

Impact . OECD LI turning: In Nov 2011 the OECD LI turned negative and fell for 15 months. In Mar-April 2016 it finally inflected positively. Peter Eadon-Clarke highlights that historically OECD LI troughs coincide with bottoms of the equities market and point to an early stage cyclical recovery where tech, materials and energy stocks tend to outperform in Japan. . Steels upgrade: On materials, Polina Diyachkina has adjusted her commodity forecasts, highlighting that for the first time this year there are more upgrades than downgrades to her assumptions. She expects metals to beat bulks and precious metals for the remainder of the year, with zinc the top performer. She has upgraded Nippon Steel (5401) from Neutral->Outperform and JFE (5411) from Underperform->Neutral as steel names are now past their earnings trough and looks for sequential recovery over the coming two to three quarters. A stronger Yen is the biggest risk for Nippon Steel. As a result we include Nippon Steel in the Marquee list. Mitsubishi Corp remains on the list as well. . Autos look interesting: As outlined in Peter’s Japan Strategy document he expects JP auto stocks to outperform. Tak Katayama recommends Suzuki in particular and hence we add to the Marquee list. . Generics: Following the initiation by Mike Allen we add Towa Pharma. The company recently raised EBIT guidance, despite increases in guidance on capital expenditures and depreciation. We think the market’s obsession with these expense items is misguided. Towa earns above-average returns on its investments and struggles to meet the demand its products are generating . MELCO adding: Damian likes Mitsubishi Elec (MELCO) as a top pick in his coverage. He expects MELCO’s shares to outperform those of FA firms with high robot and MT exposure, building off recent price momentum. He sees MELCO as a leader in FA, air conditioners and power semiconductors. . Daiwa House swap: Following the confirmation of an IPO for Takara Leben of its solar assets and strong mid-term plans we remove it and replace with Analyst(s) Daiwa House for domestic property expansion. Will still likes Takara Leben David Gibson, CFA and looks to FY3/18 for a residential JREIT IPO as a catalyst. +81 3 3512 7880 [email protected]

. Out: We have removed Fast Retailing, Takara Leben (IPO catalyst has 15 June 2016 passed), Cookpad (management changes will take a while to work out), Macquarie Capital Securities (Japan) Matsumotokiyoshi and Kakaku (catalyst has passed). Limited

Please refer to page 4 for important disclosures and analyst certification, or on our website www.macquarie.com/research/disclosures.

Macquarie Research Macquarie Marquee Ideas

Analysis

Fig 1 New Marquee List Upside/ Security Analyst Name Company Name Rec Price Price Target Downside %

1925 William Montgomery Daiwa House Industry Outperform 3062 4200 37.17 3003 William Montgomery Hulic Outperform 1046 1800 72.08 4553 Mike Allen Towa Pharmaceutical Outperform 5930 8100 36.59 5401 Polina Diyachkina Nippon Steel Sumitomo Metal Outperform 1956.5 2600 32.89 6503 Damian Thong Mitsubishi Electric Corporation Outperform 1260 1600 26.98 6752 Damian Thong Panasonic Corporation Outperform 906 1420 56.73 6954 Kenjin Hotta Fanuc Underperform 16155 13500 -16.43 7269 Takuo Katayama Suzuki Motor Outperform 2708 3700 36.63 8058 Polina Diyachkina Mitsubishi Corp Outperform 1831 2500 36.54 Source: FactSet, Macquarie Research, June 2016

Nippon Steel

. We have upgraded Nippon Steel to Outperform as we believe the stock has exhausted negative catalysts, the earnings have bottomed, Asian steel is unlikely to get any worse from here and domestic demand should pick up in 2H vs a soft couple of years. The major risk is a stronger yen. We see Nippon Steel as a survivor in a tough steel industry able to benefit from the downturn through M&A. Our TP is based on 13x 3/17-3/19 earnings. . Steel margins are under pressure following the rally in 1Q but the stock is already back to December 2015 levels while it is unlikely export margins will be as bad going forward. Hulic . Hulic’s share price has begun to outperform after a strong showing in 1H. Hulic’s primary earnings driver remains redevelopment of 120 legacy properties with key holdings in valuable retail/tourism driven locations such as Ginza, Yurakucho and Omotesando. By redeveloping, Hulic has quadrupled NOI in some instances by increasing rent and floor area ratio (FAR). An emerging driver is Hulic’s aggressive capital recycling and acquisition of an expanding portfolio of hotels and nursing homes which increases exposure to the themes of tourism and the aging population. Hulic has 41% upside to our RNAV. We believe the current share price only reflects the value of near- term visible EBITDA through 2016 and that the market is not yet fully pricing in the value of redevelopment of valuable properties in Nihonbashi, Ginza and Omotesando. We believe upside comes as more future projects are announced, and as acquired projects boost NOI. Mitsubishi

. Reasons to buy the stock: 1) extremely low valuations, the stock is trading on 0.4x P/BV, low even assuming that there will be resource asset impairments due to declines in oil and metals prices; 2) solid non-resource portfolio, stable Y250bn net profit pa and cashflow Y300-350bn pa; 3) company focus on positive FCF, aggressive asset divestments (Y1trn over the past three years); 4) new president from April 2016 and a new mid-term plan to be announced in May 2016 with more focus on shareholder returns (we believe the company will embrace a stable dividend policy and will raise the dividend to offset the negative impact from a dividend cut in 2015 which management now admits was a mistake). . Why now: 1) the company balance sheet is strong enough that it could afford large impairments at its FY3/16 result in May 2016, “clean the house” which will provide a fresh start for the new president; the larger the write-downs the better; 2) new president from April to focus on streamlining multiple portfolios within the company replicating his experience in the living essentials division (he has successfully sold non-core businesses in the living essentials division over the years he spent as group CEO); 3) we think the material names oversold on China concerns and that we are not seeing a hard landing in China, a relief rally to lift all boats, but we recommend this high-quality name which underperformed due to a dividend cut in 2015.

15 June 2016 2 Macquarie Research Macquarie Marquee Ideas

Panasonic . We see Panasonic as a prime beneficiary of stronger Japan domestic demand for appliances, electrical fixtures and fittings and lighting products, ahead of the consumption tax hike and in tandem with intensified real estate development activity. Longer term, we see sustained growth in its Automotive business, including ADAS/car infotainment and lithium ion batteries. We expect it to indicate plans for sustained growth, including via M&A, at its investor meeting in late March. We forecast a sustained OP CAGR of 6%. In our view, the shares were particularly attractive by late- February, being at a 30-year low in terms of absolute EV and EV/EBITDA. Towa Pharma

. Towa recently raised EBIT guidance, despite increases in guidance on capital expenditures and depreciation. We think the market’s obsession with these expense items is misguided. Towa earns above-average returns on its investments and struggles to meet the demand its products are generating. . The company’s R&D expenses should be fully capitalized, while valuation gains and losses on long-term hedges should be ignored. After these adjustments, we think 3/17 implied guidance would have to be 30% higher. We continue to think the market is irrationally penalizing Towa for actions taken by management that add value to the firm. . We think the stock is still severely under-valued. Based on a price/cash flow ratio of 7.9x EPS, which would still be a 30% discount to market leader Sawai, we set a target of 8,100. Suzuki

. Expected continued growth of the Indian auto market combined with its dominant position within that market, Suzuki should enjoy robust earnings growth over the medium term. With a clear structural tailwind, Suzuki remains our top pick over the next 6-12 months. . We employ a sum-of-parts valuation to derive our 12-month TP, valuing Maruti Suzuki and the Suzuki parent separately. For Maruti Suzuki, we utilize Indian auto analyst Amit Mishra’s TP and apply a 10% holding company discount. We use price-to-book valuation for the Suzuki-parent component, as it is in ‘rebuild’ mode, and to reflect the risks of rebuilding, we apply a 20% discount. As inherent discounts are embedded in our TP, we see potential upside beyond our ¥3,700 TP. Fanuc . We expect Fanuc (6954) to Underperform over the next 12-months driven by our view that its margins are likely to remain significantly weak over the next one to two years and believe consensus expectations remain too optimistic. We also don’t see any near-term positive catalysts that could drive a multiple expansion nor do we think its valuation levels are extremely cheap. While our OP forecast for FY3/17 is only slightly below consensus (¥142bn MRE vs ¥150bn consensus), our OP forecast for FY3/18 is roughly 17% below market expectations due to lower revenue and weaker OPM. In terms of revenue, we think the key gap is likely driven by our more cautious outlook on near-term growth in robotics demand and possibly Robomachines. For our OPM forecast, we assume that costs continue to increase YoY in FY3/18 driven by factors such as depreciation. Other companies mentioned in this report: Fast Retailing (9983 JP, ¥28,330, Outperform, TP: ¥40,000) Takara Leben (8897 JP, ¥726, Outperform, TP: ¥1,000, William Montgomery) Kakaku.com (2371 JP, ¥1,939, Underperform, TP: ¥1,660, David Gibson) Matsumotokiyoshi (3088 JP, ¥5,620, Outperform, TP: ¥9,000) Cookpad Inc (2193 JP, ¥1,335, Outperform, TP: ¥2,850, David Gibson)

15 June 2016 3 Macquarie Research Macquarie Marquee Ideas Important disclosures: Recommendation definitions Volatility index definition* Financial definitions Macquarie - Australia/New Zealand This is calculated from the volatility of historical All "Adjusted" data items have had the following Outperform – return >3% in excess of benchmark return price movements. adjustments made: Neutral – return within 3% of benchmark return Added back: goodwill amortisation, provision for Underperform – return >3% below benchmark return Very high–highest risk – Stock should be catastrophe reserves, IFRS derivatives & hedging, expected to move up or down 60–100% in a year IFRS impairments & IFRS interest expense Benchmark return is determined by long term nominal – investors should be aware this stock is highly Excluded: non recurring items, asset revals, property GDP growth plus 12 month forward market dividend speculative. revals, appraisal value uplift, preference dividends & yield minority interests Macquarie – Asia/Europe High – stock should be expected to move up or Outperform – expected return >+10% down at least 40–60% in a year – investors should EPS = adjusted net profit / efpowa* Neutral – expected return from -10% to +10% be aware this stock could be speculative. ROA = adjusted ebit / average total assets Underperform – expected return <-10% ROA Banks/Insurance = adjusted net profit /average Medium – stock should be expected to move up total assets Macquarie – South Africa or down at least 30–40% in a year. ROE = adjusted net profit / average shareholders funds Outperform – expected return >+10% Gross cashflow = adjusted net profit + depreciation Neutral – expected return from -10% to +10% Low–medium – stock should be expected to *equivalent fully paid ordinary weighted average Underperform – expected return <-10% move up or down at least 25–30% in a year. number of shares Macquarie - Canada Outperform – return >5% in excess of benchmark return Low – stock should be expected to move up or All Reported numbers for Australian/NZ listed stocks Neutral – return within 5% of benchmark return down at least 15–25% in a year. are modelled under IFRS (International Financial Underperform – return >5% below benchmark return * Applicable to Asia/Australian/NZ/Canada stocks Reporting Standards). only Macquarie - USA Outperform (Buy) – return >5% in excess of Russell Recommendations – 12 months 3000 index return Note: Quant recommendations may differ from Neutral (Hold) – return within 5% of Russell 3000 index Fundamental Analyst recommendations return Underperform (Sell)– return >5% below Russell 3000 index return

Recommendation proportions – For quarter ending 31 March 2016 AU/NZ Asia RSA USA CA EUR Outperform 50.34% 59.09% 46.67% 44.76% 60.66% 46.12% (for global coverage by Macquarie, 3.72% of stocks followed are investment banking clients) Neutral 34.14% 25.66% 32.00% 49.90% 30.33% 35.10% (for global coverage by Macquarie, 4.79% of stocks followed are investment banking clients) Underperform 15.52% 15.26% 21.33% 5.33% 9.02% 18.78% (for global coverage by Macquarie, 2.31% of stocks followed are investment banking clients)

Company-specific disclosures:

Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures.

Analyst certification: We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group’s Investment Banking activities. General disclaimers: Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited and its Taiwan branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie Equities South Africa (Pty) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FCA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Country-specific disclaimers: Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organisation of the Australian Securities Exchange. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd, a participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Macquarie Capital Markets North America Ltd., which is a registered broker- dealer and member of FINRA, accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd in the United States and sent to US persons. Any US person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd should do so with Macquarie Capital Markets North America Ltd. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Germany: In 15 June 2016 4 Macquarie Research Macquarie Marquee Ideas Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Conduct Authority (No. 193905). and in Germany by BaFin. France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the , Inc. and Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), formerly known as Macquarie Capital (India) Pvt. Ltd., 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: In Taiwan, research is issued and distributed by Macquarie Capital Securities Ltd, Taiwan Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Thailand: In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thai-iod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId=MDIS03002001000000&serviceId=SDIS03002 001000. South Africa: In South Africa, research is issued and distributed by Macquarie Equities South Africa (Pty) Ltd, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie Equities South Africa (Pty) Ltd and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.’s affiliate’s analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019. © Macquarie Group

15 June 2016 5 9

Asia Research Head of Equity Research Software and Internet Transport & Infrastructure Peter Redhead (Global – Head) (852) 3922 4836 Wendy Huang (Asia) (852) 3922 3378 Janet Lewis (Asia) (852) 3922 5417 Matt Nacard (Asia – Head) (852) 3922 1362 David Gibson (Asia) (813) 3512 7880 Azita Nazrene (ASEAN) (603) 2059 8980 Jake Lynch (Asia – Head) (852) 3922 3583 Hillman Chan (China, Hong Kong) (852) 3922 3716 Corinne Jian (Taiwan) (8862) 2734 7522 Nitin Mohta (India) (9122) 6720 4090 Automobiles/Auto Parts Nathan Ramler (Japan) (813) 3512 7875 Utilities & Renewables Janet Lewis (China) (852) 3922 5417 Prem Jearajasingam (Malaysia) (603) 2059 8989 Alan Hon (Hong Kong) (852) 3922 3589 Zhixuan Lin (China) (8621) 2412 9006 Oil, Gas and Petrochemicals Inderjeetsingh Bhatia (India) (9122) 6720 4087 Amit Mishra (India) (9122) 6720 4084 Prem Jearajasingam (Malaysia) (603) 2059 8989 Lyall Taylor (Indonesia) (6221) 2598 8489 James Hubbard (Asia) (852) 3922 1226 Karisa Magpayo (Philippines) (632) 857 0899 Takuo Katayama (Japan) (813) 3512 7856 Aditya Suresh (Asia) (852) 3922 1265 James Hong (Korea) (822) 3705 8661 Duke Suttikulpanich (ASEAN) (65) 6601 0148 Commodities Abhishek Agarwal (India) (9122) 6720 4079 Banks and Non-Bank Financials Colin Hamilton (Global) (4420) 3037 4061 Polina Diyachkina (Japan) (813) 3512 7886 Ian Roper (65) 6601 0698 Matthew Smith (China) (8621) 2412 9022 Anna Park (Korea) (822) 3705 8669 Jim Lennon (4420) 3037 4271 Suresh Ganapathy (India) (9122) 6720 4078 Isaac Chow (Malaysia) (603) 2059 8982 Lynn Zhao (8621) 2412 9035 Lyall Taylor (Indonesia) (6221) 2598 8489 Pharmaceuticals and Healthcare Matthew Turner (4420) 3037 4340 Keisuke Moriyama (Japan) (813) 3512 7476 Rakesh Arora (9122) 6720 4093 Leo Nakada (Japan) (813) 3512 6050 Wei Li (China, Hong Kong) (852) 3922 5494 Chan Hwang (Korea) (822) 3705 8643 Abhishek Singhal (India) (9122) 6720 4086 Economics Gilbert Lopez (Philippines) (632) 857 0892 Property Peter Eadon-Clarke (Global) (813) 3512 7850 Thomas Stoegner (Singapore) (65) 6601 0854 Larry Hu (China, Hong Kong) (852) 3922 3778 Dexter Hsu (Taiwan) (8862) 2734 7530 Tuck Yin Soong (Asia, Singapore) (65) 6601 0838 Tanvee Gupta Jain (India) (9122) 6720 4355 Passakorn Linmaneechote (Thailand) (662) 694 7728 David Ng (China, Hong Kong) (852) 3922 1291 Quantitative / CPG Conglomerates Raymond Liu (China, Hong Kong) (852) 3922 3629 Wilson Ho (China) (852) 3922 3248 Gurvinder Brar (Global) (4420) 3037 4036 Gilbert Lopez (Philippines) (632) 857 0892 Abhishek Bhandari (India) (9122) 6720 4088 Woei Chan (Asia) (852) 3922 1421 William Montgomery (Japan) (813) 3512 7864 Consumer and Gaming Anthony Ng (Asia) (852) 3922 1561 Aiman Mohamad (Malaysia) (603) 2059 8986 Danny Deng (Asia) (852) 3922 4646 Linda Huang (China, Hong Kong) (852) 3922 4068 Kervin Sisayan (Philippines) (632) 857 0893 Per Gullberg (Asia) (852) 3922 1478 Zibo Chen (Hong Kong) (852) 3922 1130 Corinne Jian (Taiwan) (8862) 2734 7522 Amit Mishra (India) (9122) 6720 4084 Patti Tomaitrichitr (Thailand) (662) 694 7727 Strategy/Country Fransisca Widjaja (Singapore) (65) 6601 0847 Resources / Metals and Mining Viktor Shvets (Asia, Global) (852) 3922 3883 Hendy Soegiarto (Indonesia) (6221) 2598 8369 Chetan Seth (Asia) (852) 3922 4769 Toby Williams (Japan) (813) 3512 7392 Coria Chow (China) (852) 3922 1181 Peter Eadon-Clarke (Japan) (813) 3512 7850 HongSuk Na (Korea) (822) 3705 8678 Rakesh Arora (India) (9122) 6720 4093 David Ng (China, Hong Kong) (852) 3922 1291 Karisa Magpayo (Philippines) (632) 857 0899 Stanley Liong (Indonesia) (6221) 2598 8381 Erwin Sanft (China, Hong Kong) (852) 3922 1516 Polina Diyachkina (Japan) (813) 3512 7886 Emerging Leaders Rakesh Arora (India) (9122) 6720 4093 Anna Park (Korea) (822) 3705 8669 Lyall Taylor (Indonesia) (6221) 2598 8489 Jake Lynch (China, Asia) (852) 3922 3583 Technology Chan Hwang (Korea) (822) 3705 8643 Aditya Suresh (Asia) (852) 3922 1265 Gilbert Lopez (Philippines) (632) 857 0892 Neel Sinha (ASEAN) (65) 6601 0562 Damian Thong (Asia, Japan) (813) 3512 7877 Conrad Werner (Singapore) (65) 6601 0182 Timothy Lam (Hong Kong) (852) 3922 1086 Allen Chang (852) 3922 1136 Jeffrey Ohlweiler (Taiwan) (8862) 2734 7512 Mike Allen (Japan) (813) 3512 7859 (China, Hong Kong, Taiwan) Alastair Macdonald (Thailand) (662) 694 7753 Kwang Cho (Korea) (822) 3705 4953 Nitin Mohta (India) (9122) 6720 4090 David Gibson (Japan) (813) 3512 7880 Industrials George Chang (Japan) (813) 3512 7854 Find our research at Janet Lewis (Asia) (852) 3922 5417 Daniel Kim (Korea) (822) 3705 8641 Macquarie: www.macquarie.com.au/research Patrick Dai (China) (8621) 2412 9082 Soyun Shin (Korea) (822) 3705 8659 Thomson: www.thomson.com/financial Inderjeetsingh Bhatia (India) (9122) 6720 4087 Patrick Liao (Taiwan) (8862) 2734 7515 Reuters: www.knowledge.reuters.com Bloomberg: MAC GO Lyall Taylor (Indonesia) (6221) 2598 8489 Louis Cheng (Taiwan) (8862) 2734 7526 Kaylin Tsai (Taiwan) (8862) 2734 7523 Factset: http://www.factset.com/home.aspx Kenjin Hotta (Japan) (813) 3512 7871 CapitalIQ www.capitaliq.com James Hong (Korea) (822) 3705 8661 Telecoms Email [email protected] for access

Insurance Nathan Ramler (Asia, Japan) (813) 3512 7875 Scott Russell (Asia, Japan) (852) 3922 3567 Danny Chu (852) 3922 4762 Thomas Stoegner (ASEAN) (65) 6601 0854 (China, Hong Kong, Taiwan) Leo Nakada (Japan) (813) 3512 6050 Abhishek Agarwal (India) (9122) 6720 4079 Chan Hwang (Korea) (822) 3705 8643 Prem Jearajasingam (Malaysia, Singapore) (603) 2059 8989 Dexter Hsu (Taiwan) (8862) 2734 7530 Kervin Sisayan (Philippines) (632) 857 0893 Passakorn Linmaneechote (Thailand) (662) 694 7728

Sales - Japan Tokyo Sales US Sales Japan Sales Trading David Shirt (Head of Equities) (813) 3512 7922 New York Matt Ryan (Head of Sales Trading) (813) 3512 7927 Nick Cant (Head of Sales) (65) 6601 0210 Paul Colaco (1 212) 231 2496 Christopher Miller (813) 3512 7831 Alisaun Binder (813) 3512 7924 Jean Zhang (1 212) 231 6397 Kazuya Kuramochi (813) 3512 7832 Eileen Lee (813) 3512 7921 Lillian Rowlatt (1 212) 231 2519 Chris Reale (1 212) 231 2616 George Hamada (813) 3512 7836 Eric Roles (1 212) 231 2559 Marc Rosa (1 212) 231 2531 Hiroyuki Yokoyama (813) 3512 7822 Christina Lee (1 212) 231 2422 Mike Keen (44) 20 3037 4905 Mark Chadwick (813) 3512 7827 Boston Naoya Kikuchi (813) 3512 7835 Mark Wild (813) 3512 7820 Jeff Evans (1 617) 598 2508 Christopher Schaffner (813) 3512 7838 Akihiro Ohara (813) 3512 7828 Shunsuke Kuriyama (813) 3512 7919 Shun Aonuma (1 617) 598 2535 San Francisco Mitsuharu Tanaka (813) 3512 7834 Europe Sales Todd Narter (1 415) 835 1239 London Ben Musgrave (44) 20 3037 4882 Julien Roux (44) 20 3037 4867 Brent Smith (44) 20 3037 4887 Geneva Thomas Renz (41) 22 818 7712